Skip to content

Study · Non-randomized trial · n = 5 · 2012

16 results

Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure.

Gafni RI, Brahim JS, Andreopoulou P, Bhattacharyya N, Kelly MH, Brillante BA, Reynolds JC, Zhou H, Dempster DW, Collins MT

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Aug 2012Cited by 60 (Europe PMC)

PMID22492501 (opens in a new tab)PMCIDPMC3399961 (opens in a new tab)DOI10.1002/jbmr.1627 (opens in a new tab)PepBankPUB-22492501
Source linkPubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid adults and adolescents, PTH 1‑34 increased bone markers to supranormal levels compared with baseline.

    In plain wordsPTH increased bone turnover markers above normal levels compared with baseline in people with hypoparathyroidism.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone turnover markers
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    hPTH 1-34 therapy significantly increased bone markers to supranormal levels.
    1 context sentence
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  2. 02HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid subjects, PTH 1‑34 increased cancellous bone volume compared with baseline.

    In plain wordsPTH increased spongy bone volume compared with baseline in people with hypoparathyroidism.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCancellous bone volume
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Histomorphometry revealed that treatment dramatically increased cancellous bone volume and trabecular number and decreased trabecular separation.
    1 context sentence
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  3. 03HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid subjects, PTH 1‑34 increased trabecular number compared with baseline.

    In plain wordsPTH increased the number of bone struts compared with baseline in people with hypoparathyroidism.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular number
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Histomorphometry revealed that treatment dramatically increased cancellous bone volume and trabecular number and decreased trabecular separation.
    1 context sentence
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  4. 04HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid subjects, PTH 1‑34 decreased trabecular separation compared with baseline.

    In plain wordsPTH decreased spacing between bone struts compared with baseline in people with hypoparathyroidism.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTrabecular separation
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Histomorphometry revealed that treatment dramatically increased cancellous bone volume and trabecular number and decreased trabecular separation.
    1 context sentence
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  5. 05HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid subjects, changes in trabecular width varied during PTH 1‑34 treatment.

    In plain wordsBone strut width changes varied during PTH treatment compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedTrabecular width
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Changes in trabecular width were variable, suggesting that the increase in trabecular number was due to the observed intratrabecular tunneling.
    1 context sentence
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  6. 06HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid subjects, cortical width remained unchanged during PTH 1‑34 treatment compared with baseline.

    In plain wordsOuter bone width remained unchanged during PTH treatment compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCortical width
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Cortical width remained unchanged; however, hPTH 1-34 treatment increased cortical porosity.
    1 context sentence
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  7. 07HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid subjects, PTH 1‑34 increased cortical porosity compared with baseline.

    In plain wordsPTH increased outer bone porosity compared with baseline in people with hypoparathyroidism.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCortical porosity
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Cortical width remained unchanged; however, hPTH 1-34 treatment increased cortical porosity.
    1 context sentence
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  8. 08HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid subjects, PTH 1‑34 stimulated cancellous remodeling with significant changes in osteoid, mineralizing surface, and bone formation rate.

    In plain wordsPTH stimulated spongy bone remodeling compared with baseline, with significant changes in formation indices.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCancellous remodeling and formation indices
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Cancellous bone remodeling was also stimulated, inducing significant changes in osteoid, mineralizing surface, and bone formation rate.
    1 context sentence
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  9. 09HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid subjects, PTH 1‑34 stimulated endocortical remodeling, similarly to cancellous remodeling.

    In plain wordsPTH stimulated remodeling at the inner cortical surface compared with baseline in people with hypoparathyroidism.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseEndocortical remodeling
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Similar changes were seen in endocortical and intracortical remodeling.
    2 context sentences
    Summary · context
    Cancellous bone remodeling was also stimulated, inducing significant changes in osteoid, mineralizing surface, and bone formation rate.
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  10. 10HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid subjects, PTH 1‑34 stimulated intracortical remodeling, similarly to cancellous remodeling.

    In plain wordsPTH stimulated remodeling within cortical bone compared with baseline in people with hypoparathyroidism.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseIntracortical remodeling
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Similar changes were seen in endocortical and intracortical remodeling.
    2 context sentences
    Summary · context
    Cancellous bone remodeling was also stimulated, inducing significant changes in osteoid, mineralizing surface, and bone formation rate.
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  11. 11HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid subjects, spine BMD Z-scores remained unchanged during PTH 1‑34 treatment compared with baseline.

    In plain wordsSpine bone density scores remained unchanged during PTH treatment compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeSpine BMD Z-score
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    BMD Z-scores were unchanged at the spine and femoral neck.
    1 context sentence
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  12. 12HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid subjects, femoral neck BMD Z-scores remained unchanged during PTH 1‑34 treatment compared with baseline.

    In plain wordsFemoral neck bone density scores remained unchanged during PTH treatment compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeFemoral neck BMD Z-score
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    BMD Z-scores were unchanged at the spine and femoral neck.
    1 context sentence
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  13. 13HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid subjects, total hip Z-scores increased during PTH 1‑34 treatment compared with baseline.

    In plain wordsTotal hip bone density scores increased during PTH treatment compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTotal hip BMD Z-score
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Total hip Z-scores increased; however, total body BMD Z-scores decreased during the first 6 months of treatment and then stabilized, remaining significantly decreased compared to baseline.
    1 context sentence
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  14. 14HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid subjects, total body BMD Z-scores decreased initially during PTH 1‑34 treatment and remained significantly below baseline after stabilization.

    In plain wordsWhole-body bone density scores decreased initially during PTH treatment and remained below baseline after stabilization.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTotal body BMD Z-score
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Total hip Z-scores increased; however, total body BMD Z-scores decreased during the first 6 months of treatment and then stabilized, remaining significantly decreased compared to baseline.
    1 context sentence
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  15. 15HumanNon-randomized trialEfficacy outcome

    In hypoparathyroid subjects, radial Z-scores decreased during PTH 1‑34 treatment, most prominently in the growing adolescent.

    In plain wordsForearm bone density scores decreased during PTH treatment compared with baseline, especially in the growing adolescent.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseRadial BMD Z-score
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Radial Z-scores also decreased with treatment; this was most pronounced in the growing adolescent.
    1 context sentence
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.
  16. 16HumanNon-randomized trialMechanism

    In hypoparathyroid adults and adolescents receiving PTH 1‑34, intratrabecular tunneling was observed in bone biopsies.

    In plain wordsIn people with hypoparathyroidism receiving PTH, bone biopsies showed tunnels within bone struts.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableIntratrabecular tunneling
    Study

    n = 5

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Individualized to maintain serum calcium at 1.9 to 2.25 mmol/L · Injection two to three times daily · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Changes in trabecular width were variable, suggesting that the increase in trabecular number was due to the observed intratrabecular tunneling.
    1 context sentence
    Summary · context
    We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.